Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

NCT05276713 · clinicaltrials.gov ↗
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Beijing 302 Hospital